Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that sustained ERK activity during tissue regeneration in spiny mice is linked to fibroblast growth factor and ErbB signaling, while inhibiting ERK shifted regeneration toward scarring.

In this study, researchers explored whether minoxidil, a common treatment for androgenetic alopecia, may have estrogenic activity and found preliminary evidence suggesting it could act as a partial agonist of Estrogen Receptor α (ERα).

This study observed that among male patients who experienced telogen effluvium after platelet-rich plasma treatment for androgenic alopecia, there were elevated levels of TNF-α, androgen receptors, and altered 5α-reductase gene expression, suggesting these factors as potential contributors to this unintended outcome.

This review explores whether SARS-CoV-2 could trigger or worsen α-synucleinopathies, like Parkinson's disease, by affecting α-synuclein misfolding and aggregation, potentially linking COVID-19 with the development of parkinsonism-like symptoms.

This study reports two cases of alopecia associated with anti-TNF therapy, highlighting a new entity combining features of alopecia areata and psoriatic alopecia.

This study found that melatonin may enhance hair follicle stem cell viability by downregulating the nuclear receptor RORA, which otherwise inhibits cell proliferation and promotes apoptosis.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This review discusses various treatment options for chronic central serous chorioretinopathy, evaluating studies conducted since 2000, but reports no new clinical results.

The study found that ondansetron decreased alcohol consumption only in adult rats that experienced altered neuroactive steroid levels from early post-natal finasteride exposure, suggesting increased 5HT3 receptor sensitivity in these rats.

This review assessed the safety of oral antiandrogen treatments for female androgenetic alopecia, finding spironolactone to be potentially safe even in high-risk populations, but indicated ongoing uncertainty regarding other medications, especially for patients with a history of gynecologic cancers.

This review discusses current treatment methods for managing androgenetic alopecia in men and women, but reports no new clinical results, highlighting the lack of a standard treatment guide.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

This study found that α-MSH acts as a modulator of inflammatory and fibrogenic responses in human fibroblastic skin cells, indicating potential therapeutic options for fibrotic skin disorders and inflammatory diseases of the hair follicle.

This review discusses the impact of medical and surgical treatments for LUTS/BPH on ejaculatory function, highlighting that most treatments negatively affect it, except for some minimally invasive surgical therapies and specific medical therapies.

This review discusses the therapeutic potential of Smoothened modulators for cancer treatment and explores their pharmacological implications, but reports no new clinical findings.

This study found that Edar signaling plays a role in regulating the hair cycle and apoptosis in hair follicle keratinocytes during the catagen phase in mice.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

This review explores current and emerging treatments for polycystic ovary syndrome, focusing on managing hyperandrogenism and cardiometabolic risk, but reports no new clinical results.

This study found that emodin from Polygonum multiflorum showed 5alpha-reductase inhibitory activity, which was more potent than alizarin but less potent than riboflavin.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.

This study found that androgen impacted glucocorticoid signaling in the mouse brain only in the prefrontal cortex and substantia nigra, suggesting limited interaction between these hormones at high corticosterone levels.

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.